US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Prescription Drugs Market Research Reports & Industry Analysis

RSS Feeds

Prescription Drugs Industry Research & Market Reports

  2    4  5  6  7  8  9  10  
Cambodia and Laos Pharmaceuticals and Healthcare Report Q1 2016
12/30/2015 | published by: BMI Research
... and higher rewards marketssuch as Vietnam means that Cambodia will remain low on investors'' priority list. Headline Expenditure Projections Pharmaceuticals: KHR910.8bn (USD228mn) in 2014 to KHR1,008.1bn (USD252mn) in 2015; +10.7%in local currency terms and US ...  |  read more...
USD 1,295
Ecuador Pharmaceuticals and Healthcare Report Q1 2016
12/30/2015 | published by: BMI Research
... the country will bemore appealing to drugmakers which report in the currency, particularly as the dollar maintains itsstrength in 2016. As the government continues to prioritise foreign investment into the country, Ecuadorwill become increasingly attractive ...  |  read more...
USD 1,295
Egypt Pharmaceuticals and Healthcare Report Q1 2016
12/30/2015 | published by: BMI Research
... policy implementation. Questions regarding financialfeasibility will also be raised; however, we note that the government is demonstrating increasing will toimplement policy reforms within the sector, boosting Egypt's attractiveness to international pharmaceuticalcompanies.Headline Expenditure Projections Pharmaceuticals: EGP29.50bn ...  |  read more...
USD 1,295
Ghana Pharmaceuticals and Healthcare Report Q1 2016
12/30/2015 | published by: BMI Research
... its presence both domestically and internationally. This wouldallow Ghana to reduce its unsustainable reliance on imported pharmaceuticals, although non-payment ofallocated funds by the government remains a risk to our outlook.Headline Expenditure ProjectionsPharmaceuticals: GHS1.01bn (USD329mn) in ...  |  read more...
USD 1,295
Kazakhstan Pharmaceuticals and Healthcare Report Q1 2016
12/30/2015 | published by: BMI Research
... Eurasian Economic Union (EAEU) will lead to access to better quality drugsat lower prices, increasing consumption as the country forms and integrates a common market forpharmaceuticals. Government expenditure on health continues to play a key ...  |  read more...
USD 1,295
Latvia Pharmaceuticals and Healthcare Report Q1 2016
12/30/2015 | published by: BMI Research
... austerity measures. As a result, despite its transparent regulatory policies andbusiness-friendly operating environment, the Latvian pharmaceutical market will continue to remain amodest prospect for drugmakers. Exports will also be impacted by regional tensions.Headline Expenditure Projections ...  |  read more...
USD 1,295
Romania Pharmaceuticals and Healthcare Report Q1 2016
12/30/2015 | published by: BMI Research
... and the expansion of pharmacies in the country. This comes as thesector is supported by positive pricing and advertising regulations in the country, thus allowing firms toleverage upon the expansion of pharmacies as well as ...  |  read more...
USD 1,295
South Africa Pharmaceuticals and Healthcare Report Q1 2016
12/30/2015 | published by: BMI Research
... such measures. The request puts pressure on AbbVie to address supply issues, butmore importantly reminds South Africa's government that expectations over the stalled efforts to amend thecountry's patent laws remain high. The government has made ...  |  read more...
USD 1,295
Actovegin -Drug Insights, 2016
1/1/2016 | published by: DelveInsight
... the total sales estimation and also provides the Actovegin sales performance during the historical period and forecast period to 2018. DelveInsight’s Report also covers the detailed clinical assessment of Actovegin, patents information and exclusivity data, ...  |  read more...
USD 1,000
Adderall -Drug Insights, 2016
1/1/2016 | published by: DelveInsight
... the total sales estimation and also provides the Adderall sales performance during the historical period and forecast period to 2018. DelveInsight’s Report also covers the detailed clinical assessment of Adderall, patents information and exclusivity data, ...  |  read more...
USD 1,000
Allelock -Drug Insights, 2016
1/1/2016 | published by: DelveInsight
... the total sales estimation and also provides the Allelock sales performance during the historical period and forecast period to 2018. DelveInsight’s Report also covers the detailed clinical assessment of Allelock, patents information and exclusivity data, ...  |  read more...
USD 1,000
Apidra Solostar -Drug Insights, 2016
1/1/2016 | published by: DelveInsight
... Apidra Solostar covering the total sales estimation and also provides the Apidra Solostar sales performance during the historical period and forecast period to 2018. DelveInsight’s Report also covers the detailed clinical assessment of Apidra Solostar, ...  |  read more...
USD 1,000
Atripla -Drug Insights, 2016
1/1/2016 | published by: DelveInsight
... the total sales estimation and also provides the Atripla sales performance during the historical period and forecast period to 2018. DelveInsight’s Report also covers the detailed clinical assessment of Atripla, patents information and exclusivity data, ...  |  read more...
USD 1,000
Avastin -Drug Insights, 2016
1/1/2016 | published by: DelveInsight
... the total sales estimation and also provides the Avastin sales performance during the historical period and forecast period to 2018. DelveInsight’s Report also covers the detailed clinical assessment of Avastin, patents information and exclusivity data, ...  |  read more...
USD 1,000
Azilekt -Drug Insights, 2016
1/1/2016 | published by: DelveInsight
... covering the total sales estimation and also provides the Azilekt sales performance during the historical period and forecast period to 2018. DelveInsight’s Report also covers the detailed clinical assessment of Azilekt , patents information and ...  |  read more...
USD 1,000
Baraklyud -Drug Insights, 2016
1/1/2016 | published by: DelveInsight
... the total sales estimation and also provides the Baraklyud sales performance during the historical period and forecast period to 2018. DelveInsight’s Report also covers the detailed clinical assessment of Baraklyud, patents information and exclusivity data, ...  |  read more...
USD 1,000
Basen -Drug Insights, 2016
1/1/2016 | published by: DelveInsight
... the total sales estimation and also provides the Basen sales performance during the historical period and forecast period to 2018. DelveInsight’s Report also covers the detailed clinical assessment of Basen, patents information and exclusivity data, ...  |  read more...
USD 1,000
Bepanthene -Drug Insights, 2016
1/1/2016 | published by: DelveInsight
... the total sales estimation and also provides the Bepanthene sales performance during the historical period and forecast period to 2018. DelveInsight’s Report also covers the detailed clinical assessment of Bepanthene, patents information and exclusivity data, ...  |  read more...
USD 1,000
Bonviva -Drug Insights, 2016
1/1/2016 | published by: DelveInsight
... the total sales estimation and also provides the Bonviva sales performance during the historical period and forecast period to 2018. DelveInsight’s Report also covers the detailed clinical assessment of Bonviva, patents information and exclusivity data, ...  |  read more...
USD 1,000
Boostrix -Drug Insights, 2016
1/1/2016 | published by: DelveInsight
... the total sales estimation and also provides the Boostrix sales performance during the historical period and forecast period to 2018. DelveInsight’s Report also covers the detailed clinical assessment of Boostrix, patents information and exclusivity data, ...  |  read more...
USD 1,000
Cialis -Drug Insights, 2016
1/1/2016 | published by: DelveInsight
... the total sales estimation and also provides the Cialis sales performance during the historical period and forecast period to 2018. DelveInsight’s Report also covers the detailed clinical assessment of Cialis, patents information and exclusivity data, ...  |  read more...
USD 1,000
Concerta -Drug Insights, 2016
1/1/2016 | published by: DelveInsight
... the total sales estimation and also provides the Concerta sales performance during the historical period and forecast period to 2018. DelveInsight’s Report also covers the detailed clinical assessment of Concerta, patents information and exclusivity data, ...  |  read more...
USD 1,000
Dalacine Injection -Drug Insights, 2016
1/1/2016 | published by: DelveInsight
... Dalacine Injection covering the total sales estimation and also provides the Dalacine Injection sales performance during the historical period and forecast period to 2018. DelveInsight’s Report also covers the detailed clinical assessment of Dalacine Injection, ...  |  read more...
USD 1,000
Diprivan EML -Drug Insights, 2016
1/1/2016 | published by: DelveInsight
... Diprivan EML covering the total sales estimation and also provides the Diprivan EML sales performance during the historical period and forecast period to 2018. DelveInsight’s Report also covers the detailed clinical assessment of Diprivan EML, ...  |  read more...
USD 1,000
Dysport -Drug Insights, 2016
1/1/2016 | published by: DelveInsight
... the total sales estimation and also provides the Dysport sales performance during the historical period and forecast period to 2018. DelveInsight’s Report also covers the detailed clinical assessment of Dysport, patents information and exclusivity data, ...  |  read more...
USD 1,000
  2    4  5  6  7  8  9  10